These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29970704)

  • 1. Study on early diagnosis of epithelial ovarian cancer by analysis of plasma septin-9 and clusterin level.
    Lyu N; Wang Y; Wang J; Zhang Z; Kong W
    J Cancer Res Ther; 2018 Jun; 14(Supplement):S444-S449. PubMed ID: 29970704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Protein levels and its clinical significance of septin-9 and clusterin in peripheral blood of epithelial ovarian cancer patients].
    Lyu N; Yao H; Xiao T; Gao Y; Wu L
    Zhonghua Fu Chan Ke Za Zhi; 2015 Sep; 50(9):679-84. PubMed ID: 26675395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.
    Arakawa N; Kobayashi H; Yonemoto N; Masuishi Y; Ino Y; Shigetomi H; Furukawa N; Ohtake N; Miyagi Y; Hirahara F; Hirano H; Miyagi E
    PLoS One; 2016; 11(10):e0165609. PubMed ID: 27798689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics.
    Odunsi K; Wollman RM; Ambrosone CB; Hutson A; McCann SE; Tammela J; Geisler JP; Miller G; Sellers T; Cliby W; Qian F; Keitz B; Intengan M; Lele S; Alderfer JL
    Int J Cancer; 2005 Feb; 113(5):782-8. PubMed ID: 15499633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer.
    Yang ZJ; Zhao BB; Li L
    J Ovarian Res; 2016 Sep; 9(1):57. PubMed ID: 27629537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
    Romagnolo C; Leon AE; Fabricio ASC; Taborelli M; Polesel J; Del Pup L; Steffan A; Cervo S; Ravaggi A; Zanotti L; Bandiera E; Odicino FE; Scattolo N; Squarcina E; Papadakis C; Maggino T; Gion M
    Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
    Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
    Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum soluble mesothelin-related peptide (SMRP): a potential diagnostic and monitoring marker for epithelial ovarian cancer.
    Wu X; Li D; Liu L; Liu B; Liang H; Yang B
    Arch Gynecol Obstet; 2014 Jun; 289(6):1309-14. PubMed ID: 24370956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
    Miao Y; Yan Q; Li S; Li B; Feng Y
    Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients.
    Będkowska GE; Ławicki S; Gacuta E; Pawłowski P; Szmitkowski M
    J Ovarian Res; 2015 May; 8():27. PubMed ID: 25935153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
    PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative angiopoietin-2 serum levels: a marker of malignant potential in ovarian neoplasms and poor prognosis in epithelial ovarian cancer.
    Sallinen H; Heikura T; Laidinen S; Kosma VM; Heinonen S; Ylä-Herttuala S; Anttila M
    Int J Gynecol Cancer; 2010 Dec; 20(9):1498-505. PubMed ID: 21119365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study.
    Wu J; Yin H; Zhu J; Buckanovich RJ; Thorpe JD; Dai J; Urban N; Lubman DM
    PLoS One; 2015; 10(3):e0121112. PubMed ID: 25799488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The conglomeration of diagnostic, prognostic and therapeutic potential of serum miR-199a and its association with clinicopathological features in epithelial ovarian cancer.
    Zuberi M; Khan I; Gandhi G; Ray PC; Saxena A
    Tumour Biol; 2016 Aug; 37(8):11259-66. PubMed ID: 26951510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Y-box protein-1/p18 as novel serum marker for ovarian cancer diagnosis: A study by the Tumor Bank Ovarian Cancer (TOC).
    Rohr I; Braicu EI; En-Nia A; Heinrich M; Richter R; Chekerov R; Dechend R; Heidecke H; Dragun D; Schäfer R; Gorny X; Lindquist JA; Brandt S; Sehouli J; Mertens PR
    Cytokine; 2016 Sep; 85():157-64. PubMed ID: 27371774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
    Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
    Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between plasma PSGL-1 and FIGO stage, tumor metastasis, and survival in epithelial ovarian cancer.
    Li W; Fang C; Gao Y; Gao Y; Yan F; Chen B; Xu M
    Biotechnol Appl Biochem; 2024 Aug; 71(4):733-740. PubMed ID: 38494670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer.
    Zou L; He X; Zhang JW
    Braz J Med Biol Res; 2010 Dec; 43(12):1232-8. PubMed ID: 21103788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?
    Montagnana M; Danese E; Ruzzenente O; Bresciani V; Nuzzo T; Gelati M; Salvagno GL; Franchi M; Lippi G; Guidi GC
    Clin Chem Lab Med; 2011 Mar; 49(3):521-5. PubMed ID: 21288178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.